Recent Updates
Recently added Catalysts
IVVD Negative Sentiment Score: 30/100

INVIVYD SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc. – IVVD, ADGI

Key Takeaway: Kahn Swick & Foti, LLC has issued a reminder to investors of Invivyd, Inc. (formerly known as Adagio Therapeutics) that they have until April 3, 2023, to file lead plaintiff applications in a class action lawsuit. This lawsuit stems from allegations that Invivyd failed to disclose critical information about its lead product candidate, ADG20, which was found to be significantly less effective against the Omicron variant of COVID-19. Following these revelations, the company's stock plummeted nearly 80% in a single day. Investors who purchased shares during the class period are encouraged to consider their legal rights and options.

Market Sentiment Analysis

CONCERNS & RISKS

  • Invivyd is facing a class action lawsuit for failing to disclose material information regarding its product's efficacy.
  • The company's stock price experienced a drastic drop of nearly 80% following negative test results, indicating significant investor trust loss.
  • There is a lead plaintiff deadline, which adds pressure on affected investors to take legal action.
  • The lawsuits arise from the company's previous assurances about the effectiveness of its COVID-19 treatment.

Full Press Release Details

NEW ORLEANS, March 22, 2023 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 3, 2023 to file lead plaintiff applications in a securities class action lawsuit against Invivyd, Inc. (the “Company”) (NasdaqGM: IVVD) f/k/a Adagio Therapeutics, Inc. (“Adagio”) (NasdaqGM: ADGI), if they purchased the Company’s shares between November 29, 2021 and December 14, 2021, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Massachusetts.
If you purchased shares of Invivyd and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgm-ivvd/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by April 3, 2023.
Invivyd and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On December 14, 2021, the Company (then named Adagio) disclosed that in vitro test results for ADG20, its lead product candidate against the COVID-19 Omicron variant, revealed that it was 300 times less effective at neutralizing Omicron than it was against the other variants, despite assuring investors of the efficacy against Omicron only a few weeks prior.
On this news, shares of Adagio plummeted nearly 80%, from $34.26 per share on December 13, 2021, to $7.26 per share when the market closed on December 14, 2021.
The case is Brill v. Invivyd, Inc., No. 23-cv-10254.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.
To learn more about KSF, you may visit www.ksfcounsel.com.
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
1100 Poydras St., Suite 960
New Orleans, LA 70163

Tags

Frequently Asked Questions

What is the deadline to file a lead plaintiff application?

The deadline to file is April 3, 2023.

What company is involved in the class action lawsuit?

The lawsuit involves Invivyd, Inc., formerly Adagio Therapeutics, Inc.

What triggered the stock price drop for Invivyd shares?

Shares dropped after it was revealed ADG20 was 300 times less effective against Omicron.

How much did Invivyd shares fall on December 14, 2021?

Shares plummeted nearly 80%, from $34.26 to $7.26.

Who should be contacted for more information about the case?

Contact KSF Managing Partner Lewis Kahn at 1-877-515-1850 or via email.

Last updated: Mar 22, 2023